Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC reduced its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 12.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 31,692 shares of the biopharmaceutical company’s stock after selling 4,536 shares during the period. Commonwealth Equity Services LLC’s holdings in Horizon Therapeutics Public were worth $1,961,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of HZNP. D.A. Davidson & CO. acquired a new position in Horizon Therapeutics Public in the first quarter valued at approximately $223,000. Synovus Financial Corp boosted its position in Horizon Therapeutics Public by 8.7% during the 1st quarter. Synovus Financial Corp now owns 11,196 shares of the biopharmaceutical company’s stock valued at $1,181,000 after purchasing an additional 895 shares during the period. Cetera Investment Advisers grew its stake in Horizon Therapeutics Public by 10.2% during the 1st quarter. Cetera Investment Advisers now owns 2,874 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 267 shares during the last quarter. Vanguard Group Inc. increased its position in Horizon Therapeutics Public by 0.9% in the first quarter. Vanguard Group Inc. now owns 20,328,877 shares of the biopharmaceutical company’s stock worth $2,138,801,000 after buying an additional 190,183 shares during the period. Finally, Loomis Sayles & Co. L P lifted its stake in Horizon Therapeutics Public by 3.3% in the first quarter. Loomis Sayles & Co. L P now owns 349,586 shares of the biopharmaceutical company’s stock valued at $36,780,000 after buying an additional 11,054 shares during the last quarter. 91.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on HZNP shares. SVB Leerink lowered shares of Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $88.00 to $116.50 in a research report on Tuesday, December 13th. StockNews.com started coverage on shares of Horizon Therapeutics Public in a research note on Friday. They issued a “buy” rating on the stock. Guggenheim cut Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and lifted their price target for the company from $98.00 to $116.50 in a report on Tuesday, December 13th. BMO Capital Markets lowered Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 13th. Finally, Stifel Nicolaus downgraded Horizon Therapeutics Public from a “buy” rating to a “hold” rating and cut their target price for the company from $138.00 to $116.50 in a research note on Monday, December 12th. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Horizon Therapeutics Public has an average rating of “Hold” and an average price target of $111.42.

Horizon Therapeutics Public Stock Down 0.5 %

HZNP opened at $109.45 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.67 and a current ratio of 3.85. The company has a market capitalization of $25.00 billion, a PE ratio of 49.08, a P/E/G ratio of 3.84 and a beta of 1.15. The stock’s fifty day moving average is $111.12 and its 200-day moving average is $89.15. Horizon Therapeutics Public Limited has a one year low of $57.84 and a one year high of $117.49.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported $1.21 EPS for the quarter, topping the consensus estimate of $1.09 by $0.12. Horizon Therapeutics Public had a net margin of 14.37% and a return on equity of 23.04%. The firm had revenue of $942.03 million for the quarter, compared to analysts’ expectations of $922.95 million. During the same period in the previous year, the business earned $1.41 earnings per share. Horizon Therapeutics Public’s revenue for the quarter was down 7.1% compared to the same quarter last year. On average, equities analysts predict that Horizon Therapeutics Public Limited will post 5.73 EPS for the current fiscal year.

Insider Activity at Horizon Therapeutics Public

In other Horizon Therapeutics Public news, EVP Andy Pasternak sold 27,129 shares of Horizon Therapeutics Public stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $113.03, for a total value of $3,066,390.87. Following the transaction, the executive vice president now owns 56,338 shares in the company, valued at $6,367,884.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Horizon Therapeutics Public news, EVP Andy Pasternak sold 27,129 shares of the company’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $113.03, for a total transaction of $3,066,390.87. Following the completion of the sale, the executive vice president now directly owns 56,338 shares of the company’s stock, valued at $6,367,884.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jeffrey W. Sherman sold 3,368 shares of Horizon Therapeutics Public stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $113.05, for a total transaction of $380,752.40. Following the completion of the transaction, the executive vice president now directly owns 39,539 shares in the company, valued at $4,469,883.95. The disclosure for this sale can be found here. Insiders sold a total of 71,832 shares of company stock valued at $8,125,648 over the last ninety days. Insiders own 2.50% of the company’s stock.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.